Sovereign s Capital Management LLC Makes New $2.81 Million Investment in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Sovereign s Capital Management LLC purchased a new stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 297,830 shares of the biopharmaceutical company's stock, valued at approximately $2,806,000. Amicus Therapeutics accounts for about 1.8% of Sovereign s Capital Management LLC's holdings, making the stock its 23rd biggest holding. Sovereign s Capital Management LLC owned about 0.10% of Amicus Therapeutics at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Park Avenue Securities LLC acquired a new position in Amicus Therapeutics during the fourth quarter worth $123,000. Avanza Fonder AB purchased a new stake in shares of Amicus Therapeutics in the fourth quarter valued at $157,000. KBC Group NV grew its position in shares of Amicus Therapeutics by 44.4% in the fourth quarter. KBC Group NV now owns 10,154 shares of the biopharmaceutical company's stock valued at $96,000 after purchasing an additional 3,120 shares during the period. R Squared Ltd purchased a new stake in Amicus Therapeutics during the fourth quarter valued at about $79,000. Finally, China Universal Asset Management Co. Ltd. grew its position in Amicus Therapeutics by 11.1% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 63,358 shares of the biopharmaceutical company's stock valued at $597,000 after acquiring an additional 6,314 shares during the period.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the company. UBS Group boosted their price target on Amicus Therapeutics from $21.00 to $22.00 and gave the company a "buy" rating in a research report on Friday, May 2nd. The Goldman Sachs Group lowered their price target on Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating for the company in a research report on Friday, May 2nd. Wall Street Zen cut Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Monday, May 5th. Wells Fargo & Company reduced their price objective on Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating on the stock in a research note on Thursday, February 20th. Finally, Needham & Company LLC restated a "hold" rating on shares of Amicus Therapeutics in a research note on Thursday, February 20th. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $16.22.

Amicus Therapeutics Price Performance

FOLD traded down $0.08 during trading on Thursday, reaching $6.26. The stock had a trading volume of 2,995,154 shares, compared to its average volume of 2,841,268. The firm has a market capitalization of $1.93 billion, a price-to-earnings ratio of -34.78, a price-to-earnings-growth ratio of 1.51 and a beta of 0.64. The company has a quick ratio of 2.42, a current ratio of 3.39 and a debt-to-equity ratio of 2.01. Amicus Therapeutics, Inc. has a 1-year low of $5.81 and a 1-year high of $12.65. The stock has a 50 day moving average of $7.22 and a two-hundred day moving average of $8.82.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.